Study Weighs Cost-Effectiveness of CGRP Inhibitors for Migraine

The Institute for Clinical and Economic Review (ICER) has released a draft evidence report assessing the clinical effectiveness and economic value of calcitonin gene-related peptide (CGRP) inhibitors for the treatment of chronic or episodic migraines.

The institute reviewed Amgen and Novartis’ erenumab, Teva’s fremanezumab, an Eli Lilly’s galcenezumab for outcomes including: frequency, intensity, and duration of migraine events; pain; cognitive functioning/impairment; disability; health-related quality of life; use of rescue therapies; tolerability; and adverse events.

ICER identified and examined existing evidence of the treatments from clinical studies of adult patients aged 18 and older with chronic or episodic migraines who were eligible for preventive migraine therapy.

Click to continue reading on The American Journal of Managed Care.